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75 y.o. female
▪ 3 year hx progressive short term memory loss
▪ 2 years ago stopped driving after she became lost
▪ Past 1-2 years speech punctuated by pauses to

▪
▪
▪
▪

find proper word or substituting inappropriate word
Past 1-2 years inability to attach names to familiar
faces
Past 6-12 months difficulty planning and preparing
her own meals and eating mostly sweets and ice
cream
Gait slowing and shuffling more recently
Increasing paranoia

Dementia
▪ Decline in cognition severe enough to
interfere with daily life ( social,
occupational, etc.)
▪ Represents a decline from previous level
of function
▪ No underlying systemic medical cause

Alzheimer’s Facts
▪ Affects 5 million in U.S ; 17 million worldwide.
▪ Affects > 30% of persons > 80 y.o.
▪ 6th leading cause of death in this country and the
▪
▪

▪

only disease among the 10th deadliest that
cannot be prevented, slowed, or cured.
By the year 2050 estimated to affect 13.5 million
people in U.S.
Accounts for 50% of cases of dementia in
autopsy and clinical series.
Occurs naturally only in humans.

Genetics
▪ 1st degree relative of a subject with late
onset AD has 2x the expected risk of
acquiring the disease.
▪ Concordance rate in twin studies
( Swedish registry ) :
59 % for monozygotic twins
35 % for same sex dizygotic twins
24 % for opposite sex dizygotic
twins

AD is pathologically characterized by the presence of
extracellular amyloid plaques (composed of
aggregated amyloid-β peptide) and intracellular
neurofibrilary tangles (composed of aggregated tau).
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Typical AD
▪ Memory loss is first and predominant
complaint

▪ Associated with a deficit in at least 1 other
cognitive domain

▪ Absence of early motor features

Core Elements of Declining Cognition
( Domains )
▪ Memory – misplaces things, repeats, forgets
▪
▪
▪

▪

conversations and appointments
Speech – expressive speech +/or comprehension
Behavior and personality ( apathetic, disinhibited,
argumentative, compulsive, paranoid )
Visuospatial – gets lost, difficulty dressing,
hallucinations
Executive – inability to make decisions, solve
problems, complete complex tasks, handle
gadgets

Mild Cognitive Impairment
▪ Concern regarding a decline in cognition
not severe enough to impact independent
living
▪ Often in one cognitive domain only and
usually affecting memory ( primarily short
term )
▪ Conversion to dementia in 10-15% / year
▪ MMSE 25-27

Mild AD

▪ Decline in 2 or more domains
▪ Still able to care for self
▪ Decreased attention
▪ Difficulty with complex tasks
▪ Work trouble
▪ Halting speech
▪ MMSE 19-24
▪ Problems at work

Moderate AD
▪ Worsening memory, confusion,
disorientation
▪ Appearance of behavioral symptoms,
wandering, restlessness
▪ Increasing aphasia
▪ More difficulty with ADLs
▪ Unable to be left alone
▪ MMSE 10-18

Advanced AD
▪ Total dependency for ADLs
▪ Worsening behavior and gait progressing
to bed and wheelchair existence

Subtypes of Alzheimer’s Disease
▪ Typical
▪ Hippocampal sparing
▪ Hippocampal predominant
▪ Clinical sx and patterns of atrophy on
MRI parallel density and distribution of
NFTs

Dementia- Etiologies
▪ Alzheimer’s disease
▪ Vascular Dementia
▪ Fronto-Temporal Lobar Dementia
▪ Lewy Body Disease
▪ Normal Pressure Hydrocephalus
▪ Others

Dementia: role of MRI updated version
Frederik Barkhof, Marieke Hazewinkel, Maja Binnewijzend
and Robin Smithuis
Alzheimer Centre and Image Analysis Centre, Vrije
Universiteit Medical Center, Amsterdam and the Rijnland
Hospital, Leiderdorp, The Netherlands
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Vascular Dementia

Vascular Dementia
▪ Stepwise progression of symptoms
secondary to recurrent strokes
▪ Gradual progression of symptoms due to
subclinical ischemia and progressive
accumulation of “ non specific T2 white
matter hyperintensities “
▪ Often coexists with Alzheimer’s pathology

Frontotemporal Dementia –
3 Major Subtypes
▪ Prominent behavioral change and
disordered social conduct
▪ Progressive nonfluent aphasia
▪ Impaired understanding of word
meaning and/or object identity

Frontotemporal Dementia
▪ Memory and visuospatial skills relatively
preserved early
▪ Pathology – Pick bodies and other various
neuronal and glial inclusions
▪ Onset often before age 65.
▪ Some cases exhibit autosomal dominant
inheritance
▪ Minority have co-existent motor neuron
disease

Divorced 60 y.o female – live alone

▪ 2 years ago fired from her job as dental
assistant
▪ Family concerned because she is
frequenting bars late at night – never did
this before
▪ Has become obsessed with getting back
with husband
▪ Beginning to have word finding problems
▪ Etiology thought to be depression

Diffuse Lewy Body Disease
▪ Impairment in memory, attention,
executive function and visuospatial ability
▪ Parkinsonism
▪ Visual hallucinations
▪ Fluctuating cognition with pronounced
variations in attention and alertness
▪ Pathology- Lewy bodies ( intraneuronal
cytoplasmic inclusions containing alphasynuclein )

69 y.o. Innkeeper

▪ 9 months ago family noticed he seemed
confused while on a cruise.
▪ confusion has worsened since
▪ Has started to see imaginary people on
property next door
▪ No longer can plan meals
▪ Up at night wandering
▪ Gait has noticeably slowed and he is
starting to shuffle

Normal Pressure Hydrocephalus
▪ Ataxia

▪ Urinary incontinence
▪ Dementia

? NPH

Rapidly Progressive Dementia
( weeks to months )
▪ Creutzfeldt - Jakob disease
▪ Toxic/metabolic
▪ Infectious
▪ Autoimmune
▪ Paraneoplastic
▪ Neurodegenerative

Dementia Evaluation
▪ Hx from pt and informant- review drug list
▪ PE including cognitive testing
▪ Screen for depression
▪ CBC, CMP, TSH,B12
▪ Brain image- CT or MRI
▪ Consider LP if rapidly progressive
▪ Consider neuropsych testing
▪ Consider EEG if ? seizures or CJD
▪ Consider PET scan

History
▪ Start with the onset of the first cognitive
symptom then develop a detailed
description for the evolution of all
subsequent areas of cognitive decline

▪ Query all domains
▪ History from patient and informant

Core Elements of Declining Cognition
( Domains )
▪ Memory – misplaces things, repeats, forgets
▪
▪
▪

▪

conversations and appointments
Speech – expressive speech +/or comprehension
Behavior and personality ( apathetic, disinhibited,
argumentative, compulsive, paranoid )
Visuospatial – gets lost, difficulty dressing,
hallucinations
Executive – inability to make decisions, solve
problems, complete complex tasks, handle
gadgets

Alzheimer's Association recommendations for
operationalizing the detection of cognitive
impairment during the Medicare Annual Wellness
Visit in a primary care setting

Alzheimer’s & Dementia - (2013) 1–10

What Is the Best Dementia Screening Instrument for
General Practitioners to Use ?
Brodaty, Henry M.B.B.S., M.D., F.R.A.C.P., F.R.A.N.Z.C.P.;
Low, Lee-Fay B.Sc.(Psych.)Hons.; Gibson, Louisa B.Sc.(Arch.),
Grad. Dip. Psych., B.Sc.(Psych.)Hons.; Burns, Kim R.N.,
B.Psych.(Hons.)

▪ GPCOG- General Practitioner Assessment of
Cognition

▪ Mini-Cog
▪ MIS
American Journal of Geriatric Psychiatry:
May 2006 - Volume 14 - Issue 5 - pp 391-400

Other Cognitive Tests
▪ Mini Mental State- copyright restricted ,
relatively insensitive to mild cognitive
impairment and non AD dementias

▪ Montreal Cognitive Assessment- more
sensitive for frontal-executive function

▪ St Louis University Mental Status
Examination ( SLUMS)

Neuropsychological Testing
▪ Labor intensive and relatively expensive
but useful in certain settings ( ex. early or
young onset )

MRI and/or CT Brain
▪ R/O treatable pathology
▪ Pattern of atrophy ? Frontal, hippocampal,
parietal

Subfrontal Meningioma

Parietal Atrophy

Central and Cortical Atrophy

Hippocampal Atrophy

Frontotemporal Dementia

Effectiveness of Cholinesterase Inhibitors and
Memantine for Treating
Dementia: Evidence Review for a Clinical Practice
Guideline
Parminder Raina, PhD; Pasqualina Santaguida,
PhD; Afisi Ismaila, MSc; Christopher Patterson,
MD; David Cowan, MD; Mitchell Levine, MD;
Lynda Booker, BSc; and Mark Oremus, PhD
Conclusions: Treatment of dementia with cholinesterase
inhibitors and memantine can result in statistically
significant but clinically marginal improvement in measures
of cognition and global assessment of dementia.
Ann Intern Med. 2008;148:379-397.

Cholinesterase Inhibitors and
Memantine
▪ Does the medication improve my patient’s
quality of life ?
▪ Is the improvement worth the cost ?
▪ What about side effects ? ( G.I.,
nightmares ? )

Syncope and Its Consequences in Patients
With Dementia Receiving Cholinesterase Inhibitors
A Population-Based Cohort Study
Sudeep S. Gill, MD, MSc; Geoffrey
M. Anderson, MD, PhD; Hadas D.
Fischer, MD; Chaim M. Bell, MD,
PhD; Ping Li, PhD; Sharon-Lise T.
Normand, PhD; Paula A. Rochon,
MD, MPH
ARCH INTERN MED/VOL 169 (NO. 9), MAY 11,
2009
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Dementia Performance
Measurement Set
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪

Staging of dementia
Cognitive assessment
Functional status assessment
Neuropsychiatric symptom assessment
Management of neuropsychiatric symptoms
Screening for depressive symptoms
Counseling regarding safety concerns
Counseling regarding risks of driving
Palliative care counseling and advance care
planning
Caregiver education and support

Pharmacological Treatment
of Neuropsychiatric Symptoms of Dementia
A Review of the Evidence
Kaycee M. Sink, MD
Karen F. Holden, MD
Kristine Yaffe, MD

JAMA, February 2, 2005—Vol 293, No. 5

Alz.org
▪ Cognitive and informant assessment
tools
▪ Diagnostic guidelines and suggested w/u
▪ 7 stages of Alzheimers
▪ Differential dx with links to other
degenerative disease sites
▪ Section on managing challenging
behaviors
▪ Links to clinical studies

Dominantly Inherited
Alzheimer’s Network ( DIAN )
▪ Worldwide network of autosomal dominant
Alzheimer’s disease centers

Original Article

Clinical and Biomarker Changes in Dominantly
Inherited Alzheimer's Disease
Randall J. Bateman, M.D., Chengjie Xiong, Ph.D., Tammie L.S. Benzinger, M.D.,
Ph.D., Anne M. Fagan, Ph.D., Alison Goate, Ph.D., Nick C. Fox, M.D., Daniel S.
Marcus, Ph.D., Nigel J. Cairns, Ph.D., Xianyun Xie, M.S., Tyler M. Blazey, B.S.,
David M. Holtzman, M.D., Anna Santacruz, B.S., Virginia Buckles, Ph.D., Angela
Oliver, R.N., Krista Moulder, Ph.D., Paul S. Aisen, M.D., Bernardino Ghetti, M.D.,
William E. Klunk, M.D., Eric McDade, M.D., Ralph N. Martins, Ph.D., Colin L.
Masters, M.D., Richard Mayeux, M.D., John M. Ringman, M.D., Martin N.
Rossor, M.D., Peter R. Schofield, Ph.D., D.Sc., Reisa A. Sperling, M.D., Stephen
Salloway, M.D., John C. Morris, M.D., for the Dominantly Inherited Alzheimer
Network

N Engl J Med
Volume 367(9):795-804
August 30, 2012

Clinical and Biomarker Changes in
Dominantly Inherited Alzheimer’s
Disease
▪ Concentration of amyloid in CSF begins to

▪
▪

▪
▪

decline 25 years before expected onset of sx.
amyloid beta detected by PET ( PiB ) 15 years
before.
Increase in CSF tau and atrophy on MRI 15
years before.
Cerebral hypometabolism ( FDG PET ) and
impaired episodic memory 10 years before
Global cognitive impairment 5 years before

Alzheimer 1864-1915

Image has been removed

Resources
▪ Caregiver & Family Resources
• Alzheimer’s Association
– Multiple sources of assistance
– 24/7 Helpline 1-800-272-3900

• Knowing the signs of caregiver stress
• Respite Care
– Private Duty Agencies
– Assisted Living for overnight stays
– Adult Day Care

Resources
▪ Patient
• Driving Evaluations to assess competency
– Good Shepherd
– Ph: 610-776-3517, Fax: 610-776-8375

• Power of Attorney & Living Will
• In-home help
– Referral to County Aging office if over 60
– Lehigh County: 610-782-3034
– Northampton County: 610-559-3270

Down’s Syndrome and AD
▪ 1929 - senile plaques noted in brains of relatively young subjects.

▪ 1948 - some patients with Down’s syndrome noted to develop
Alzheimer type dementia in their 30’s and 40’s.

▪ 1958 - Down’s syndrome associated with extra copy of chromosome
21.

▪ mid 1980‘s Woman in Nottingham England alerts Al;zheimer’s
researcher at St. Mary’s Hospital in London to high incidence of AD
in her father’s family. Mutated gene found to reside on chromosome
21

▪ 1987 – gene for amyloid precursor protein linked to chromosome 21

